While enrollment to that study largely predated the routine use of trastuzumab in the adjuvant setting for HER2-positive breast cancer patients, a small number (n = 12) of HER2-positive patients were vaccinated after completion of an adjuvant systemic therapy regimen that included trastuzumab [9]. Here, ERBB2 is linked to breast cancer.